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The male-to-female sex ratio at birth is constant across world populations with an average of 1.06 (106 male to
100 female live births) for populationsof Europeandescent. The sex ratio is considered tobe affectedbynumer-
ous biological and environmental factors and to have a heritable component. The aim of this study was to in-
vestigate the presence of common allele modest effects at autosomal and chromosome X variants that could
explain the observed sex ratio at birth. We conducted a large-scale genome-wide association scan (GWAS)
meta-analysis across 51 studies, comprising overall 114 863 individuals (61 094 women and 53 769 men) of
European ancestry and 2 623 828 common (minor allele frequency >0.05) single-nucleotide polymorphisms
(SNPs). Allele frequencies were compared between men and women for directly-typed and imputed variants
within each study. Forward-time simulations for unlinked, neutral, autosomal, common loci were performed
under the demographic model for European populations with a fixed sex ratio and a random mating scheme
to assess the probability of detecting significant allele frequency differences. We do not detect any genome-
wide significant (P < 5 3 1028) common SNP differences between men and women in this well-powered
meta-analysis. The simulated data provided results entirely consistent with these findings. This large-scale in-
vestigation across ∼115 000 individuals shows no detectable contribution from common genetic variants to
the observed skew in the sex ratio. The absence of sex-specific differences is useful in guiding genetic associ-
ation study design, for example when using mixed controls for sex-biased traits.
INTRODUCTION
The male-to-female sex ratio at birth is very constant across
world populations, ranging between 1.02 and 1.08 (102–108
male to 100 female live births), with an average of 1.06 for
populations of European descent (1–3). The sex ratio at
birth is mainly determined by factors influencing the
primary sex ratio, which is the sex ratio at conception, and
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those influencing the survival of the embryo (4). Frequently
reported primary sex ratio-determining factors include motility
and survival time of X-bearing and Y-bearing sperm. A
proportion of prenatal mortality can be attributable to im-
munological interaction between mother and embryo (4).
Interestingly, more males are being born in spite of the fact
that there is higher mortality of males than females during
intrauterine life (4,5). In addition, the sex ratio is considered
to be affected by numerous other biological (endogenous)
and environmental (exogenous) factors, albeit their influence
is generally thought to be of a small effect (1,6). These
factors include gonadotropins and/or testosterone concentra-
tion at the time of conception, ovulation induction, parental
age, parity, birth order, coital rates, infertility, parental
illness, maternal malnutrition, smoking, exposure to certain
chemicals, stress, war, socioeconomic status and many
others (1,6–8). The variation in sex ratio was also observed
in many animal and plant species (9). Studies of parasitoid
wasps, particularly Nasonia vitropennis, identified several
quantitative trait loci (QTL) associated with the sex ratio,
pointing to a genetic contribution (9). In addition, many
authors suggest that the human sex ratio also has a heritable
component. Paternal effects have been proposed to play a
role in the sex ratio, for example, men with more brothers
tend to have more sons whereas men with more sisters tend
to have more daughters (5,10,11). Based on population genet-
ics modelling, Gellatly et al. (11) suggested that the sex ratio
is determined by common inheritance of polymorphic auto-
somal genes that exert their effect through the male reproduct-
ive system. Another study of reproductive fitness in the
Hutterite population suggested that genetic variants, both auto-
somal and X-linked, influence natural fertility in humans (12).
Research of human births in two-child families observed that
sexes of offspring do not follow a binomial model of inherit-
ance where probability of having a boy equals probability of
having a girl (13). This study also pointed to the lack of inde-
pendence among sexes of children of the same parents (13). A
couple of possible genetic mechanisms underlying this obser-
vation such as Y- and X-linked immunological incompatibil-
ities between mother and embryo have been proposed (13,14).
In the present study, we test whether common variant genetic
effects partly underlie the observed male-to-female sex ratio at
birth. To address this, we investigate the presence of autosomal
and chromosome X variant differences between men and
women across 114 863 individuals through large-scale genome-
wide association study (GWAS) meta-analysis. We also
conduct a forward-time simulation study to assess the probabil-
ity of observing significant allele frequency differences at auto-
somal markers between men and women. Our study has high
power to detect loci with modest to small effect sizes.
RESULTS
GWAS meta-analysis results
Initial meta-analysis results pointed to an excess of associa-
tions compared with the null distribution (Fig. 1A). We exam-
ined all genome-wide significant SNPs with effective sample
size .10 000 to check for false positives due to genotyping
error or other artefacts. We investigated three main diagnostic
metrics: poor cluster plots in men or women (Supplementary
Material, Fig. S1), sequence similarity on chromosome Y
and exact Hardy–Weinberg equilibrium (HWE), P , 1.0 ×
1026 for men or women. Autosomal SNPs that lie in
genomic regions that have sequence similarity on the Y
chromosome may be incorrectly genotyped/called in men,
but not in women, which may give rise to false-positive asso-
ciations. This can be traced through several quality control
(QC) checks in men: excess of heterozygosity, deviation
from HWE and poor cluster plots in men and not in women.
Some/all of these factors were observed for SNPs designated
for exclusion from follow-up (all with highly significant asso-
ciation P-values). We excluded SNPs from the pseudoautoso-
mal chromosome X boundary regions (within 55 kb on the
short arm of chromosome X and 115 kb on the long arm
that lie next to the non-pseudoautosomal regions) to guard
Figure 1. QQ plots for 2 623 828 directly genotyped and imputed SNPs: (A)
for all examined SNPs; (B) after exclusion of poorly genotyped/called SNPs.
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against genotyping error in men (for example, caused by the
presence of truncated copies of genes and/or mappings to mul-
tiple places across the genome). After exclusion of all poorly
genotyped/called SNPs, we detect a single genome-wide sig-
nificant association at a non-pseudoautosomal chromosome
X variant (rs12689384, P ¼ 2.66 × 10213), which is an intron-
ic variant within RBMX2. As this SNP was imputed in all
studies driving the association, we checked cluster plots of
all directly typed variants 500 kb upstream and downstream
of the associated SNP in all studies, excluded SNPs with
poor clustering, re-imputed the region and re-run the
meta-analysis. The significance of rs12689384 dropped by
five orders of magnitude (allele G, OR ¼ 1.18, 95% CI
[1.11–1.25], P ¼ 3.27 × 1028) but remained nominally
genome-wide significant. However, there are several factors
that reduce the credibility of this finding. First, 12 studies in
total contributed summary statistics for this variant (for a
total of 33 259 individuals), out of which six WTCCC1
studies drive the association (Supplementary Material,
Table S1). This SNP is imputed in all WTCCC1 studies. Sec-
ondly, as shown in the regional association plot (Supplemen-
tary Material, Fig. S2), this SNP lacks support for
association from neighbouring variants. The next most statis-
tically strong association in the region is modest (P ¼
1.99 × 1024) and observed at an SNP (rs2294956) which is
in perfect linkage disequilibrium with rs12689384 (r2¼ 1,
D’ ¼ 1) based on HapMap CEU, on which imputation was
based. This second SNP (rs2294956) is also imputed in the
WTCCC1 studies, but in fact the meta-analysis includes data
from over twice the sample size (31 studies, 67 162 indivi-
duals, Supplementary Material, Table S1). All studies contrib-
uting directly typed data for this variant (46 066 individuals
with directly typed data) show no evidence for association,
indicating that the signal observed at the imputed variant
may be an artefact. We have therefore not considered this
single associated SNP any further.
The distribution of association P-values after meta-analysis
QC was consistent with the null (Fig. 1B). Our study has 80%
power to detect OR of 1.13 (at a ¼ 5 × 1028) for SNPs with
minor allele frequency (MAF) .5%, assuming an additive
model. We did not further examine SNPs with P-values
above the genome-wide significance threshold since our
study had sufficient power to detect associations of loci with
small-to-modest effect sizes.
Simulation study results
Association analysis of 1 337 699 autosomal common and 135
988 autosomal low-frequency variants in the simulated case–
control set matching the empirical study did not identify any
differences in allele frequencies between men and women
(a ¼ 5 × 1028). Quantile–quantile (QQ) plots for simulated
common and low-frequency variants are shown in Supplemen-
tary Material, Figure S3.
DISCUSSION
This large-scale investigation across 114 863 individuals iden-
tified no detectable contribution from common genetic
variants to the observed skew in sex ratio at birth. This
study combined the data from 51 cohorts and has excellent
power to detect small-to-modest effect sizes at common loci.
The sample sizes contributing to the analysis of chromosome
X SNPs were lower due to limited overlap of directly typed
SNPs across platforms (in the absence of imputed data
across all studies). However, power remains high at over
80% to detect small-to-modest effect sizes. From the pheno-
typic aspect, sex is a well-characterized trait representing an
additional strength of this study, which is unlikely to suffer
from phenotype misclassification.
Our results, within the power constraints of our study, indi-
cate that sex-specific selection against particular autosomal
genetic variants is not a plausible explanation for the observed
male-to-female sex ratio at birth and argue against the hypoth-
esis that incompatible genotypes at common variants between
the autosomes and sex chromosomes could lead to miscar-
riage, thus generating sex-specific genetic differences. We per-
formed forward-time simulations of 1.3 million independent
autosomal, common, neutral loci, conditioning on the
male-to-female sex ratio at birth, in a cohort matching the ori-
ginal study sample. The lack of any significant allele fre-
quency differences between men and women was in keeping
with the findings of the GWAS meta-analysis for autosomal
SNPs. We also tested the effects of low-frequency variants
in the simulated data, and found no evidence for association
with the observed sex ratio at birth. However, we cannot
rule out the effects of rare, structural or chromosome Y var-
iants since these were not analysed in our study.
Sex chromosome loci may be relevant for the sex ratio
determination due to their expression in the reproductive
system, their role in spermatogenesis, sperm morphogenesis
and movement and male–female fertility in general (15,16).
Therefore, we performed a comprehensive chromosome X ana-
lysis involving two main chromosome X regions: pseudoautoso-
mal and non-pseudoautosomal. There are two pseudoautosomal
regions (PAR1 and PAR2), which are homologous on X and Y
chromosomes, and for which men and women carry two
alleles per SNP, whereas for the non-pseudoautosomal region
men carry only one allele per SNP. We investigated allele
frequency differences between men and women in both chromo-
some X regions and we observed the association of one non-
pseudoautosomal SNP (rs12689384) just below the genome-wide
significance level. For various reasons expanded in the Results
section, we believe that this variant may be an imputation artefact
and have thus not taken it forward to further studies.
The investigated dataset consisted of more women (61 094)
than men (53 769). Our meta-analysis incorporated summary
statistics deriving from 51 collaborating studies and the vast
majority of these studies (36 studies) are population based.
The main difference in the sex ratio is driven by these popu-
lation based studies and the reasons for having fewer men
can be heterogeneous and study specific. Most likely the
main reasons are the generally recognized lower male re-
sponse to take part in epidemiological population-based
studies (17) and/or sex differences in longevity where
women have a higher expected lifespan (18). Fifteen of the
51 contributing studies are disease- rather than population-
based and the sex ratio in these studies approximately corre-
sponds to the disease sex ratio in the population. We were
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driven by the rationale that the sex ratio at birth is constant
throughout time and across all world populations, meaning
that common variants are more likely to underlie the observed
sex ratio at birth. Therefore, in the case of a higher male death
rate, we would still have enough power to detect common
variant differences due to a very large sample set. However,
there are scenarios where this sampling difference between
men and women might cause bias, for example there may be
a genetic variant that is influencing both the sex ratio and lon-
gevity in men. In that case, higher male death rate would cause
the removal of this specific genetic variant, thus masking the
signal.
Our results have important implications for genetic associ-
ation study design, for example regarding the selection of
control sets for sex-biased traits such as prostate cancer in
men or anorexia nervosa in women. The use of single-sex con-
trols for sex-specific diseases generally decreases the sample
size and power of a study. Our findings demonstrate that
mixed sex controls can be used as an appropriate set in
studies of sex-specific traits, when focusing on common loci.
As one additional implication for genetic association study
analyses, our study stresses the importance of careful pre-
and post-analysis QC. QQ plots of our initial meta-analysis
results showed high deviation from the null, yet, after QC
we observe no inflation of signal. A robust and thorough QC
pipeline is necessary to verify any positive association
signals, especially in meta-analyses where many studies con-
tribute data that were genotyped (and phenotyped) in many
different settings.
We conclude that common genetic variants do not play a
role in defining male-to-female sex ratio at birth. In this
large-scale meta-analysis of 115 000 individuals, we found
no allele frequency differences at common loci between men
and women. Simulated data of autosomal neutral variants
support these findings. Our results can be useful in informing
GWAS study design, especially when using mixed controls for
sex-biased traits.
MATERIALS AND METHODS
Study samples
We conducted genome-wide meta-analysis across 51 studies,
comprising overall 114 863 individuals (61 094 women and
53 769 men) of European ancestry. The characteristics of
samples from contributing studies are presented in Supple-
mentary Material, Table S2.
Ethics statement
Each study obtained ethical approval from their respective
research ethics committee and all participants gave signed
informed consent in accordance with the Declaration of Helsinki.
Genotyping, imputation and QC
All samples were genotyped using commercially available
Illumina (Illumina, Inc., San Diego, CA, USA) or Affymetrix
(Affymetrix, Inc., Santa Clara, CA, USA) platforms. Imput-
ation of missing genotypes was based on HapMap Phase II
genotypes for the European population (CEU). QC of directly
typed and imputed variants was conducted separately in each
study. Study-specific information on genotyping platforms,
imputation methods and QC metrics is presented in Supple-
mentary Material, Table S3. QC checks included tests for
relatedness among samples within individual studies.
Genome-wide association analysis of autosomal variants
Case–control association analysis of autosomal SNPs was
conducted under the additive model, for directly typed and
imputed variants, within each study. Women were coded as
cases and men as controls. Association analyses of imputed
variants took genotype uncertainty into account, with the ex-
ception of the QIMR study which conducted analysis on best-
guess genotypes. Where necessary, the first three genotype-
based principal components were used as covariates. Studies
with related individuals additionally adjusted analyses for
family relatedness using linear mixed models. Study-specific
association analysis software is presented in Supplementary
Material, Table S3.
Chromosome X analysis
Each contributing study performed two separate chromosome
X analyses, including pseudoautosomal and non-
pseudoautosomal regions. Association analyses were per-
formed, as per autosomes, under the additive model. Overall,
42 studies performed analysis of pseudoautosomal region, 11
of these imputed data using HapMap Phase II, all others
used directly typed variants only. For non-pseudoautosomal
region, 46 studies performed association analysis, 12 of
these used HapMap Phase II imputed data whereas others
used directly typed variants only. Study-specific chromosome
X imputation/association analysis software is presented in
Supplementary Material, Table S3.
GWAS meta-analysis
We performed fixed and random effects meta-analysis to syn-
thesize summary statistics results across contributing studies
to identify autosomal and chromosome X common SNP differ-
ences between men and women. For meta-analysis purposes,
we used GWAMA (19). Prior to meta-analysis, we excluded
SNPs with MAF lower than 0.05 and SNPs with low imput-
ation accuracy scores. Specifically, we used a cut-off of
rsq_hat , 0.3 for genotypes imputed with MACH (20),
BEAGLE (21) and PLINK (22) software and a cut-off of
proper info score ,0.5 for IMPUTE (23) software. Overall,
2 623 828 directly genotyped and imputed SNPs passed QC
criteria and were included in the meta-analysis. The genomic
control (GC) inflation factor (lambda) was calculated and
applied to correct the results for each study separately prior
to the meta-analysis. The meta-analysis results were also cor-
rected for overall lambda GC. The average GC inflation factor
across studies was 1.005 for directly genotyped SNPs, 0.97 for
imputed SNPs and 1.007 overall, suggesting little population
stratification. To determine the effective number of individuals
for each study, we calculated effective number of cases
(N_eff_case) and multiplied it by 2. N_eff_case was derived
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using the formula N_eff_case ¼ 2 × N_case × N_ctrl/
(N_case + N_ctrl), where N_case and N_ctrl is the number
of cases (women) and controls (men), respectively. We inves-
tigated evidence of heterogeneity using the I2 statistic (24).
Genome-wide significance was set to 5 × 1028. We created
QQ plots to visualize meta-analysis association results. The
power of our study was determined using QUANTO (25).
Simulation study
To exclude the possibility that our null results for autosomal
variants are due to either sampling bias or data quality and
to examine the probability of having false positives within
the power constraints of our study, we sought a theoretical cor-
roboration of our empirical results by conducting association
analysis in an ‘ideal’ unbiased simulated dataset. Simulated
genetic data were produced by means of forward-time simula-
tion (26–28) under a model of a single population with two
bottlenecks according to Schaffner et al. (29) with two excep-
tions: recent exponential growth of population size (instead
of instantaneous changes) and final effective population size
of 106 (instead of 105), as this has been shown to be the
case for the European population (30). Demographic model
parameters are given in Supplementary Material, Table S4.
The generation time was assumed to be 25 years, and the mu-
tation rate per site per generation was 1.5 × 1028 (29). We
applied a fixed sex ratio and a random mating scheme (i.e.
parents are randomly selected irrespective of their genotype)
validated by different genetic and demographic models (27).
We set a probability of having a male offspring to 0.5122,
which corresponds to a male-to-female ratio of 1.05. Simula-
tions were run for 17 000 generations after which we randomly
sampled women and men matching the original study for
sample size (women ¼ 61 094; men ¼ 53 769).
We simulated unlinked, neutral, autosomal common var-
iants with initial MAF of 0.02 in the founder population
(27,31). The total number of simulated loci was 56 502 900,
out of which 2.4% were common (MAF. 0.05). We per-
formed allele-based chi-squared association tests on the 1
337 699 common loci. This figure matches the estimated
number of independent SNPs in HapMap CEU samples of
around 1 million (32). We additionally performed allele-based
Fishers exact association tests on 135 988 low-frequency var-
iants (MAF 0.01–0.05). Supplementary Material, Figure S4
shows the MAF spectrum for simulated data compared with
the 1000 Genomes Project Pilot 3 CEU (2n ¼ 60) data.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
ACKNOWLEDGMENTS
The authors are grateful to David Clayton, Shaun Purcell and
Reedik Magi for their helpful contribution.
WTCCC: This study makes use of data generated by the
Wellcome Trust Case Control Consortium. A full list of the
investigators who contributed to the generation of the data is
available in the Supplementary Material and at www.wtccc.
org.uk. Funding for the project was provided by the Wellcome
Trust under award 076113.
AGES: The researchers are indebted to the participants for
their willingness to participate in the study. This study has
been funded by NIH contract N01-AG-1-2100, the NIA Intra-
mural Research Program, Hjartavernd (the Icelandic Heart
Association), and the Althingi (the Icelandic Parliament).
The study is approved by the Icelandic National Bioethics
Committee, VSN: 00-063.
ARIC: The Atherosclerosis Risk in Communities Study is
carried out as a collaborative study supported by National
Heart, Lung, and Blood Institute contracts (HHSN26820
1100005C, HHSN268201100006C, HHSN268201100007C,
HHSN268201100008C, HHSN268201100009C, HHSN26820
1100010C, HHSN268201100011C, and HHSN2682011
00012C), R01HL087641, R01HL59367 and R01HL086694;
National Human Genome Research Institute contract
U01HG004402; and National Institutes of Health contract
HHSN268200625226C. The authors thank the staff and parti-
cipants of the ARIC study for their important contributions.
Infrastructure was partly supported by Grant Number
UL1RR025005, a component of the National Institutes of
Health and NIH Roadmap for Medical Research.
BLSA: The BLSA was supported in part by the Intramural
Research Program of the NIH, National Institute on Aging. A
portion of that support was through a R&D contract with
MedStar Research Institute.
CoLaus: The authors express their gratitude to the partici-
pants in the Lausanne CoLaus study and to the investigators
who have contributed to the recruitment. We would like to
thank Drs Vincent Mooser and Dawn Waterworth from
GlaxoSmithKline for helpful comments and for their con-
tinuous support for the CoLaus project. Part of the computa-
tion has been performed on the Vital-IT cluster (www.vita
l-it.ch). We are grateful to Dr. Toby Johnson and Pr. Sven
Bergmann for statistical discussions. The CoLaus study
was supported by research grants from GlaxoSmithKline;
the Faculty of Biology and Medicine of Lausanne, Switzer-
land; and the Swiss National Science Foundation (grant
no:33CSCO-122661). Ge´rard Waeber and Peter Vollenwei-
der received an unrestricted grant from GSK to build the
CoLaus study.
CROATIA-Korcula: We would like to acknowledge the
staff of several institutions in Croatia that supported the field
work, including but not limited to The University of Split
and Zagreb Medical Schools and Croatian Institute for
Public Health. The SNP genotyping for the CROATIA-
Korcula cohort was performed in Helmholtz Zentrum
Mu¨nchen, Neuherberg, Germany. The CROATIA-Korcula
study was funded by grants from the Medical Research
Council (UK), and Republic of Croatia Ministry of Science,
Education and Sports research (108-1080315-0302).
CROATIA-Split: We would like to acknowledge the staff
of several institutions in Croatia that supported the field
work, including but not limited to The University of Split
and Zagreb Medical Schools and Croatian Institute for
Public Health. The SNP genotyping for the CROATIA-Split
cohort was performed by AROS Applied Biotechnology,
Aarhus, Denmark. The CROATIA-Split study is funded by
grants from the Medical Research Council (UK) and Republic
Human Molecular Genetics, 2012, Vol. 21, No. 21 4811
of Croatia Ministry of Science, Education and Sports research
grants to I.R. (108-1080315-0302).
CROATIA-Vis: We would like to acknowledge the staff of
several institutions in Croatia that supported the field work, in-
cluding but not limited to The University of Split and Zagreb
Medical Schools, Institute for Anthropological Research in
Zagreb and Croatian Institute for Public Health. The SNP
genotyping for the CROATIA-Vis cohort was performed in
the core genotyping laboratory of the Wellcome Trust Clinical
Research Facility at the Western General Hospital, Edinburgh,
Scotland, UK. The CROATIA-Vis study was funded by grants
from the Medical Research Council (UK), European Commis-
sion Framework 6 project EUROSPAN (Contract No.
LSHG-CT-2006-018947) and Republic of Croatia Ministry
of Science, Education and Sports research grants
(108-1080315-0302).
ECHRS-Spain: Spanish Ministry of Science and Innov-
ation grant MTM2008-02457; Fondo de Investigaciones San-
tarias grants 97/0035-01, 99/0034-01 and 99/0034-02;
Hospital Universitario de Albacete; Consejeria de Sanidad;
FWO (Fund for Scientific Research) grant G.0402.00; Univer-
sity of Antwerp; the Flemish Health Ministry; Sociedad Espa-
n˜ola de Neumologı´a y Cirugı´a Tora´cica (SEPAR), Public
Health Service grant R01 HL62633-01; Consell Interdeparta-
mental de Recerca i Innovacio´ Tecnolo`gica (CIRIT) grant
1999SGR 00241; Red Respira Instituto de Salud Carlos III
(ISCIII).
EGCUT: EGCUT received financial support from FP7 pro-
grams (ENGAGE, OPENGENE), targeted financial support
from Estonian Government SF0180142s08, Estonian Research
Roadmap through Estonian Ministry of Education and Re-
search, Center of Excellence in Genomics (EXCEGEN) and
University of Tartu (SP1GVARENG). The work of K.F. was
supported by Estonian Science Foundation grant EstSF
ETF9353. We acknowledge EGCUT technical personnel,
especially Mr V. Soo and S. Smit. Data analyzes were
carried out in part in the High Performance Computing
Center of University of Tartu.
ENGAGE: This research was supported through funds
from The European Community’s Seventh Framework
Programme (FP7/2007-2013), ENGAGE Consortium, grant
agreement HEALTH-F4-2007-201413.
EPIC-Obesity: The EPIC Norfolk Study is funded by
program grants from the Medical Research Council UK and
Cancer Research UK.
FENLAND: We are grateful to all the volunteers for their
time and help, and to the General Practitioners and practice
staff for help with recruitment. We thank the Fenland Study
co-ordination team and the Field Epidemiology team of the
MRC Epidemiology Unit for recruitment and clinical testing.
Ineˆs Barroso and spouse own stock in Incyte Ltd and Glaxo-
SmithKline.
FUSION: We would like to thank the many Finnish volun-
teers who generously participated in our study. The Center for
Inherited Disease Research performed the GWA genotyping.
National Institutes of Health DK062370.
GerMIFS: Supported by the Deutsche Forschungsge-
meinschaft and the German Federal Ministry of Education
and Research (BMBF) in the context of the German National
Genome Research Network (NGFN-2 and NGFN-plus), the
FP6 and FP7 EU funded integrated projects Cardiogenics
(LSHM-CT-2006-037593) and ENGAGE (201413), and the
bi-national BMBF/ANR funded project CARDomics
(01KU0908A). Supported by the DZHK (Deutsches Zentrum
fu¨r Herz-Kreislauf-Forschung – German Centre for Cardio-
vascular Research) and by the BMBF (German Ministry of
Education and Research).
HBCS: Helsinki Birth Cohort Study has been supported by
grants from the Academy of Finland (Grant No. 120315 and
129287 to EW, 1129457 and 1216965 to KR, 120386 and
125876 to JGE), the Finnish Diabetes Research Society, Fol-
kha¨lsan Research Foundation, Novo Nordisk Foundation,
Finska La¨karesa¨llskapet, the European Science Foundation
(EuroSTRESS), the Wellcome Trust (Grant No. 89061/Z/09/
Z and 089062/Z/09/Z), Samfundet Folkha¨lsan, Finska La¨kare-
sa¨llskapet and the Signe and Ane Gyllenberg foundation.
InCHIANTI: We thank the Intramural Research Program
of the NIH, National Institute on Aging who are responsible
for the InCHIANTI samples. We also thank the InCHIANTI
participants. The InCHIANTI study baseline (1998-2000)
was supported as a ‘targeted project’ (ICS110.1/RF97.71) by
the Italian Ministry of Health and in part by the U.S. National
Institute on Aging (Contracts: 263 MD 9164 and 263 MD
821336); the InCHIANTI Follow-up 1 (2001-2003) was
funded by the U.S. National Institute on Aging (Contracts:
N.1-AG-1-1 and N.1-AG-1-2111); the InCHIANTI Follow-
ups 2 and 3 studies (2004-2010) were financed by the U.S.
National Institute on Aging (Contract: N01-AG-5-0002); sup-
ported in part by the Intramural research program of the
National Institute on Aging, National Institutes of Health, Bal-
timore, Maryland. JRBP is funded by a Sir Henry Wellcome
Postdoctoral Fellowship (092447/Z/10/Z).
INGI-CARLANTINO and INGI-FVG: The study was
funded Regione FVG (L.26.2008). We thank Laura Esposito,
Angela D’Eustacchio and Emmanouil Athanasakis for tech-
nical support. We are very grateful to the municipal adminis-
trators for their collaboration on the project and for logistic
support. We would like to thank all participants to this study.
INGI-VB: We thank the inhabitants of the VB that made
this study possible, the local administrations, the Tortona
and Genova archdiocese and the ASL-22, Novi Ligure (Al)
for support. We also thank Cinzia Sala and Clara Camaschella
for data collection supervision and organization of the clinical
data collection, Fiammetta Vigano` for technical help, Corrado
Masciullo and Massimiliano Cocca for building the analysis
platform. The research was supported by funds from Compag-
nia di San Paolo, Torino, Italy; Fondazione Cariplo, Italy and
Ministry of Health, Ricerca Finalizzata 2008 and Telethon,
Italy to DT. The funders had no role in study design, data col-
lection and analysis, decision to publish, or preparation of the
manuscript.
KORA: The KORA authors acknowledge the contribution
of Peter Lichtner, Gertrud Eckstein, Guido Fischer and all
members of the Helmholtz Center Munich genotyping staff
for generating the SNP data, as well as all members of field
staffs who were involved in the planning and conduction of
the KORA Augsburg studies. The KORA research platform
was initiated and financed by the Helmholtz Center Munich,
German Research Center for Environmental Health, which is
funded by the German Federal Ministry of Education and
4812 Human Molecular Genetics, 2012, Vol. 21, No. 21
Research (BMBF) and by the State of Bavaria. Part of this
work was financed by the German National Genome Research
Network (NGFN-2 and NGFNPlus: 01GS0823). Our research
was supported within the Munich Center of Health Sciences
(MC Health) as part of LMUinnovativ.
NBS: We thank the participants from the Municipality of
Nijmegen for their continued support to the Nijmegen Bio-
medical Study. The study was partly funded by an investment
grant of the Radboud University Nijmegen Medical Centre.
NESDA: Neuroscience Campus Amsterdam; EMGO+ In-
stitute for Health and Care Research; NIMH R01
MH059160; Geestkracht program of ZonMW (10-000-1002);
matching funds from universities and mental health care insti-
tutes involved in NESDA. Genotyping was funded by the
Genetic Association Information Network (GAIN) of the
Foundation for the US National Institutes of Health, and ana-
lysis was supported by grants from GAIN and the NIMH
(MH081802).
NTR: We thank the twins and their families for their par-
ticipation.
NTR1: Funding was obtained from the Netherlands Heart
Foundation (90.313, 86.083 and 88.042), the Netherlands Or-
ganization for Scientific Research (NWO: MagW/ZonMW):
Genetic basis of anxiety and depression (904-61-090); Genet-
ics of individual differences in smoking initiation and persist-
ence (NWO 985-10-002); Resolving cause and effect in the
association between exercise and well-being (904-61-193);
Twin family database for behaviour genomics studies
(480-04-004); Twin research focusing on behaviour
(400-05-717); Genetic determinants of risk behaviour in rela-
tion to alcohol use and alcohol use disorder
(Addiction-31160008); Genotype/phenotype database for be-
haviour genetic and genetic epidemiological studies
(911-09-032); Spinozapremie (SPI 56-464-14192); CMSB:
Center for Medical Systems Biology (NWO Genomics);
NBIC/BioAssist/RK/2008.024); BBMRI –NL: Biobanking
and Biomolecular Resources Research Infrastructure; the VU
University: Institute for Health and Care Research
(EMGO+) and Neuroscience Campus Amsterdam (NCA);
the European Science Foundation (ESF): Genomewide ana-
lyses of European twin and population cohorts (EU/
QLRT-2001-01254); European Community’s Seventh Frame-
work Program (FP7/2007-2013): ENGAGE
(HEALTH-F4-2007-201413); the European Science Council
(ERC) Genetics of Mental Illness (230374); Rutgers Univer-
sity Cell and DNA Repository cooperative agreement
(NIMH U24 MH068457-06); Collaborative study of the genet-
ics of DZ twinning (NIH R01D0042157-01A); the Genetic As-
sociation Information Network, a public–private partnership
between the NIH and Pfizer Inc., Affymetrix Inc. and Abbott
Laboratories.
NTR2: Funding is acknowledged from the Netherlands Or-
ganization for Scientific Research (NWO: MagW/ZonMW):
Twin family database for behaviour genomics studies
(480-04-004); Twin research focusing on behaviour
(400-05-717); Genetic determinants of risk behaviour in rela-
tion to alcohol use (Addiction-31160008); Genotype/pheno-
type database for behaviour genetic and genetic
epidemiological studies (911-09-032); Spinozapremie (SPI
56-464-14192); CMSB: Center for Medical Systems Biology
(NWO Genomics); NBIC/BioAssist/RK/2008.024); BBMRI
–NL: Biobanking and Biomolecular Resources Research In-
frastructure; European Science Foundation (ESF): Genome-
wide analyses of European twin and population cohorts
(EU/QLRT-2001-01254); European Community’s Seventh
Framework Program (FP7/2007-2013): ENGAGE
(HEALTH-F4-2007-201413); the European Science Council
(ERC) Genetics of Mental Illness (230374); Rutgers Univer-
sity Cell and DNA Repository cooperative agreement
(NIMH U24 MH068457-06).
ORCADES: ORCADES DNA extractions were performed
at the Wellcome Trust Clinical Research Facility in Edin-
burgh. We would like to acknowledge the invaluable contribu-
tions of Lorraine Anderson and the research nurses in Orkney,
the administrative team in Edinburgh and the people of
Orkney. ORCADES was supported by the Chief Scientist
Office of the Scottish Government, the Royal Society and
the European Union framework program 6 EUROSPAN
project (contract no. LSHG-CT-2006-018947).
PREVEND: PREVEND genetics is supported by the Dutch
Kidney Foundation (Grant E033), The Netherlands Heart
Foundation (Grant 2006B140, 2006T003), National Institutes
of Health (grant LM010098, HL65234, HL67466,
RR018787) and the EU project grant GENECURE (FP-6
LSHM CT 2006 037697). P.vd.H is supported by NWO
VENI grant 91676170 and Dutch Inter University Cardiology
Institute Netherlands (ICIN).
QIMR: We thank the twins and their families for their par-
ticipation. We also thank Dixie Statham, Ann Eldridge,
Marlene Grace, Kerrie McAloney (sample collection); Anjali
Henders, Megan Campbell, Lisa Bowdler and Steven Crooks
(sample and DNA processing); Scott Gordon, David Smyth,
Harry Beeby, and Daniel Park (IT support). We also acknow-
ledge David Duffy, Peter Visscher, Margaret Wright, Pamela
Madden and Wendy Slutske for their funding contributions.
Genotype imputation was carried out on the Genetic Cluster
Computer. Funding was provided by the Australian National
Health and Medical Research Council (NHMRC grants
241944, 339462, 389927, 389875, 389891, 389892, 389938,
442915, 442981, 496739, 552485, 552498), the Australian Re-
search Council (ARC grants A7960034, A79906588,
A79801419, DP0770096, DP0212016, DP0343921), the
FP-5 GenomEUtwin Project (QLG2-CT-2002-01254), and
the U.S. National Institutes of Health (NIH grants AA07535,
AA10248, AA13320, AA13321, AA13326, AA14041,
MH66206). The Genetic Cluster Computer is financially
supported by the Netherlands Scientific Organization
(NWO 480-05-003). G.W.M. was supported by an NHMRC
Fellowship (619667), D.R.N. (FT0991022) and S.E.M.
(FT110100548) were supported by an ARC Future Fellowship.
RAINE: The authors are grateful to the Raine Study partici-
pants and their families and to the Raine Study research staff for
cohort coordination and data collection. The authors gratefully
acknowledge the NH&MRC for their long term contribution to
funding the study over the last 20 years and also the following
Institutions for providing funding for Core Management of the
Raine Study: The University of Western Australia (UWA),
Raine Medical Research Foundation, UWA Faculty of Medi-
cine, Dentistry and Health Sciences, The Telethon Institute
for Child Health Research and Women and Infants Research
Human Molecular Genetics, 2012, Vol. 21, No. 21 4813
Foundation. The authors gratefully acknowledge the assistance
of the Western Australian DNA Bank (National Health and
Medical Research Council of Australia National Enabling Facil-
ity). The authors also acknowledge the support of the National
Health and Medical Research Council of Australia (Grant ID
403981 and ID 003209) and the Canadian Institutes of Health
Research (Grant ID MOP-82893).
RS: We thank Pascal Arp, Mila Jhamai, Marijn Verkerk,
and Lisbeth Herrera for their help in creating the GWAS data-
base. The authors are grateful to the study participants, the
staff from the Rotterdam Study and the participating general
practitioners and pharmacists. We would like to thank Dr.
Tobias A. Knoch, Karol Estrada, Luc V. de Zeeuw, Anis Abu-
seiris and Rob de Graaf as well as their institutions the
Erasmus Computing Grid, Rotterdam, The Netherlands, and
especially the national German MediGRID and Services@Me-
diGRID part of the German D-Grid for access to their grid
resources. The generation and management of GWAS geno-
type data for the Rotterdam Study is supported by the Nether-
lands Organisation of Scientific Research NWO Investments
(nr. 175.010.2005.011, 911-03-012). This study is funded by
the Research Institute for Diseases in the Elderly (014-93-
015; RIDE2), the Netherlands Genomics Initiative (NGI) –
Netherlands Consortium of Healthy Aging (NCHA) project
nr. 050-060-810, and funding from the European Commission
(HEALTH-F2-2008-201865, GEFOS; HEALTH-F2-2008-
35627, TREAT-OA). The Rotterdam Study is funded by
Erasmus Medical Center and Erasmus University, Rotterdam,
Netherlands Organization for the Health Research and Devel-
opment (ZonMw), the Research Institute for Diseases in the
Elderly (RIDE), the Ministry of Education, Culture and
Science, the Ministry for Health, Welfare and Sports, the
European Commission (DG XII) and the Municipality of Rot-
terdam. German MediGRID and Services@MediGRID are
part of the German D-Grid and are both funded by the
German Bundesministerium fuer Forschung und Technology
under grants #01 AK 803 A-H and # 01 IG 07015 G.
SHIP: We thank all staff members and participants of the
SHIP study, as well as all of the genotyping staff for generat-
ing the SHIP SNP data set. The genetic data analysis workflow
was created using the Software InforSense. Genetic data were
stored using the database Cache´ (InterSystems). SHIP is part
of the Community Medicine Research net of the University
of Greifswald, Germany, which is funded by the Federal Min-
istry of Education and Research (grants no. 01ZZ9603,
01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs
as well as the Social Ministry of the Federal State of
Mecklenburg-West Pomerania, and the network ‘Greifswald
Approach to Individualized Medicine (GANI_MED)’ funded
by the Federal Ministry of Education and Research (grant
03IS2061A). Genome-wide data have been supported by the
Federal Ministry of Education and Research (grant no.
03ZIK012) and a joint grant from Siemens Healthcare, Erlan-
gen, Germany and the Federal State of Mecklenburg- West
Pomerania. The University of Greifswald is a member of the
‘Center of Knowledge Interchange’ program of the Siemens AG.
SORBS: We thank all those who participated in the study.
Sincere thank is given to Peter Kovacs who was significantly
involved in the planning and procedure of the Sorbs study. We
also thank Knut Krohn (Microarray Core Facility of the
Interdisciplinary Centre for Clinical Research, University of
Leipzig) for the genotyping support and Inga Prokopenko
and Nigel W. Rayner (WTCHG, University of Oxford, UK)
for the excellent analytical and bioinformatics support. This
work was supported by grants from the Interdisciplinary
Centre for Clinical Research at the University of Leipzig
(B27 to A.T.) from the German Diabetes Association (to
A.T.), a Travel Grant from BIF (to A.T.) and by the DHFD,
Diabetes Hilfs- und Forschungsfonds Deutschland. The work
of Vasiliki Lagou was funded through the ENGAGE (Euro-
pean Network for Genetic and Genomic Epidemiology) Con-
sortium, the European Community’s Seventh Framework
Programme (HEALTH-F4-2007-201413).
TwinsUK: We thank the staff from the TwinsUK, the DNA
Collections and Genotyping Facilities at the Wellcome Trust
Sanger Institute for sample preparation; Quality Control of
the Twins UK cohort for genotyping (in particular Amy
Chaney, Radhi Ravindrarajah, Douglas Simpkin, Cliff Hinds,
and Thomas Dibling); Paul Martin and Simon Potter of the
DNA and Genotyping Informatics teams for data handling;
Le Centre National de Ge´notypage, France, led by Mark
Lathrop, for genotyping; Duke University, North Carolina,
USA, led by David Goldstein, for genotyping; and the
Finnish Institute of Molecular Medicine, Finnish Genome
Center, University of Helsinki, led by Aarno Palotie. The
authors declare they have no conflicts of interest. The study
was funded by the Wellcome Trust; European Community’s
Seventh Framework Programme (FP7/2007-2013)/grant
agreement HEALTH-F2-2008-ENGAGE and the European
Union FP-5 GenomEUtwin Project (QLG2-CT-2002-01254)
and Framework 6 Project EUroClot. The study also receives
support from the National Institute for Health Research
(NIHR) comprehensive Biomedical Research Centre award
to Guy’s & St Thomas’ NHS Foundation Trust in partnership
with King’s College London.
YFS: The Cardiovascular Risk in Young Finns study (YFS)
is supported by the Academy of Finland (grant no. 117797,
121584 and 126925), the Social Insurance Institution of
Finland, University Hospital Medical funds to Tampere, and
Turku University Hospitals, the Finnish Foundation of Cardio-
vascular Research Emil Aaltonen Foundation (T.L), and
Tampere Tuberculosis Foundation.
Conflict of Interest statement. None declared.
FUNDING
V.B. is supported by Unity Through Knowledge Fund CON-
NECTIVITY PROGRAM (‘Gaining Experience’ Grant 2A),
The National Foundation for Science, Higher Education and
Technological Development of the Republic of Croatia
(BRAIN GAIN—Postdoc fellowship) and the Wellcome Trust
(098051). E.Z. is supported by the Wellcome Trust (098051).
Funding to pay the Open Access publication charges for this
article was provided by the Wellcome Trust (098051).
REFERENCES
1. Mackenzie, C.A., Lockridge, A. and Keith, M. (2005) Declining sex ratio
in a first nation community. Environ. Health Perspect., 113, 1295–1298.
4814 Human Molecular Genetics, 2012, Vol. 21, No. 21
2. Kaba, A.J. (2008) Sex ratio at birth and racial differences: why do black
women give birth to more females than non-black women? Afr. J.
Reprod. Health, 12, 139–150.
3. James, W.H. (1987) The human sex ratio. Part 1: a review of the literature.
Hum. Biol., 59, 721–752.
4. Chahnazarian, A. (1988) Determinants of the sex ratio at birth: review of
recent literature. Soc. Biol., 35, 214–235.
5. Curtsinger, J.W., Ito, R. and Hiraizumi, Y. (1983) A two-generation study
of human sex-ratio variation. Am. J. Hum. Genet., 35, 951–961.
6. Dodds, L. and Armson, B.A. (1997) Is Canada’s sex ratio in decline?
CMAJ, 156, 46–48.
7. James, W.H. (2004) Further evidence that mammalian sex ratios at birth
are partially controlled by parental hormone levels around the time of
conception. Hum Reprod, 19, 1250–1256.
8. Fukuda, M., Fukuda, K., Shimizu, T., Andersen, C.Y. and Byskov, A.G.
(2002) Parental periconceptional smoking and male: female ratio of
newborn infants. Lancet, 359, 1407–1408.
9. Pannebakker, B.A., Watt, R., Knott, S.A., West, S.A. and Shuker, D.M.
(2011) The quantitative genetic basis of sex ratio variation in Nasonia
vitripennis: a QTL study. J. Evol. Biol., 24, 12–22.
10. Trichopoulos, D. (1967) Evidence of genetic variation in the human sex
ratio. Hum. Biol., 39, 170–175.
11. Gellatly, C. (2009) Trends in population sex ratios may be explained by
changes in the frequencies of polymorphic alleles of a sex ratio gene.
Evol. Biol., 36, 190–200.
12. Kosova, G., Abney, M. and Ober, C. Colloquium papers: heritability of
reproductive fitness traits in a human population. Proc. Natl Acad. Sci.
USA, 107(Suppl 1), 1772–1778.
13. Carlton, M.A. and Stansfield, W.D. (2005) Making babies by the flip of a
coin? Am. Statist., 59, 180–182.
14. Stansfield, W.D. and Carlton, M.A. (2007) Human sex ratios and sex
distribution in sibships of size 2. Hum. Biol., 79, 255–260.
15. Burgoyne, P.S. (1998) The role of Y-encoded genes in mammalian
spermatogenesis. Sem. Cell Dev. Biol., 9, 423–432.
16. Zhang, Y.E., Vibranovski, M.D., Landback, P., Marais, G.A. and Long,
M. (2010) Chromosomal redistribution of male-biased genes in
mammalian evolution with two bursts of gene gain on the X chromosome.
PLoS Biol., 8, pii: e1000494.
17. McCarty, C., Wilke, R., Giampietro, P., Wesbrook, S. and Caldwell, M.
(2005) Marshfield Clinic Personalized Medicine Research Project
(PMRP): design, methods and recruitment for a large population-based
biobank. Person. Med., 2, 49–79.
18. May, R.C. (2007) Gender, immunity and the regulation of longevity.
Bioessays, 29, 795–802.
19. Magi, R. and Morris, A.P. (2010) GWAMA: software for genome-wide
association meta-analysis. BMC Bioinformatics, 11, 288.
20. Li, Y., Ding, J. and Abecasis, G. (2006) Mach 1.0: rapid haplotype
reconstruction and missing genotype inference. Am. J. Hum. Genet., 79,
S2290.
21. Browning, S.R. and Browning, B.L. (2007) Rapid and accurate haplotype
phasing and missing-data inference for whole-genome association studies
by use of localized haplotype clustering. Am. J. Hum. Genet., 81, 1084–
1097.
22. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A.,
Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J. et al. (2007)
PLINK: a tool set for whole-genome association and population-based
linkage analyses. Am. J. Hum. Genet., 81, 559–575.
23. Marchini, J., Howie, B., Myers, S., McVean, G. and Donnelly, P. (2007) A
new multipoint method for genome-wide association studies by
imputation of genotypes. Nat. Genet., 39, 906–913.
24. Higgins, J.P., Thompson, S.G., Deeks, J.J. and Altman, D.G. (2003)
Measuring inconsistency in meta-analyses. BMJ, 327, 557–560.
25. Gauderman, W.J. (2003) Candidate gene association analysis for a
quantitative trait, using parent-offspring trios. Genet. Epidemiol., 25,
327–338.
26. Peng, B., Amos, C.I. and Kimmel, M. (2007) Forward-time simulations of
human populations with complex diseases. PLoS Genet., 3, e47.
27. Peng, B. and Kimmel, M. (2007) Simulations provide support for the
common disease-common variant hypothesis. Genetics, 175, 763–776.
28. Peng, B. and Kimmel, M. (2005) simuPOP: a forward-time population
genetics simulation environment. Bioinformatics, 21, 3686–3687.
29. Schaffner, S.F., Foo, C., Gabriel, S., Reich, D., Daly, M.J. and Altshuler,
D. (2005) Calibrating a coalescent simulation of human genome sequence
variation. Genome Res., 15, 1576–1583.
30. Coventry, A., Bull-Otterson, L.M., Liu, X., Clark, A.G., Maxwell, T.J.,
Crosby, J., Hixson, J.E., Rea, T.J., Muzny, D.M., Lewis, L.R. et al. (2010)
Deep resequencing reveals excess rare recent variants consistent with
explosive population growth. Nat. Commun., 1, 131.
31. Reich, D.E. and Lander, E.S. (2001) On the allelic spectrum of human
disease. Trends Genet., 17, 502–510.
32. Pe’er, I., Yelensky, R., Altshuler, D. and Daly, M.J. (2008) Estimation of
the multiple testing burden for genomewide association studies of nearly
all common variants. Genet. Epidemiol., 32, 381–385.
Human Molecular Genetics, 2012, Vol. 21, No. 21 4815
